Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleOral Delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report.
Author(s)Hasan A, Rothenberger A, Münchau A, Wobrock T, Falkai P, Roessner V.
Journal, Volume, IssueJ Clin Psychopharmacol. 2010 Apr;30(2):190-2.
Major outcome(s)THC improved tics allowing parallel stimulant treatment of comorbid ADHD.
IndicationTourette's syndromeAbstract
MedicationDelta-9-THC

OBJECTIVE: To describe the clinical course of the Delta 9-tetrahydrocannabinol (Delta 9-THC) treatment of a boy with Gilles de la Tourette Syndrome (TS) and comorbid attention-deficit/hyperactivity disorder (ADHD) in relation to Delta 9-THC plasma levels and intracortical inhibition measured by transcranial magnetic stimulation. METHODS: The clinical course and pharmacological and neurophysiological measures are reported in a 15-year-old boy with treatment refractory TS plus ADHD leading to severe physical and psychosocial impairment. RESULTS: Administration of Delta 9-THC improved tics considerably without adverse effects, allowing parallel stimulant treatment of comorbid ADHD. Along with the Delta 9-THC treatment, intracortical inhibition was increased, reflected in the enhanced short-interval intracortical inhibition and the prolongation of the cortical silent period. CONCLUSIONS: Our observation suggests that Delta 9-THC might be a successful alternative in patients with severe TS refractory to classic treatment. Particularly in the case of stimulant-induced exacerbation of tics, Delta 9-THC might enable successful treatment of comorbid ADHD. The enhancement of intracortical inhibition might be mediated by modulating release of several neurotransmitters including dopamine and gamma-aminobutyric acid. Further studies are needed to substantiate our findings.

Route(s)Oral
Dose(s)
Duration (days)
ParticipantsA 15 year old boy with Tourette syndrome and ADHD.
DesignUncontrolled case report
Type of publicationMedical journal
Address of author(s)Department of Psychiatry and Psychotherapy, Georg-August-University Göttingen, Göttingen, Germany.
Full text

[Back to Overview]  [IACM Homepage]


up